Rare genetic conditions are frequent risk factors for, or direct causes of, organ failure requiring paediatric intensive care unit (PICU) support. Such conditions are frequently suspected but unidentified at PICU admission. Compassionate and effective care is greatly assisted by definitive diagnostic information. There is therefore a need to provide a rapid genetic diagnosis to inform clinical management.
Introduction
An increasing proportion of critically ill children have one or more chronic diseases that contribute to, or directly precipitate, paediatric intensive care admission (1). Rare genetic conditions are present in a significant proportion of elective and emergency admissions.
Uncertainty about diagnosis and often prognosis contributes to the difficulty of planning optimal care. Achieving a rapid molecular diagnosis in critically ill children with a rare genetic disease may improve the basis for such plans including informing on the potential value of highly invasive treatments (2, 3) . Reaching a genetic diagnosis also precludes the need for further diagnostic investigations, which may be invasive, painful, and expensive (4) .
For the family, a molecular diagnosis enables accurate genetic counselling and ends the diagnostic odyssey (5) . However, obtaining a genetic diagnosis in a timely manner in critically ill individuals is frequently challenging and often not possible. Factors preventing a rapid genetic diagnosis include heterogeneity of disease, limited availability of broad genetic testing, long time frames involved in standard diagnostic molecular testing, and limited knowledge of the molecular basis for most genetic disorders.
Recent advances in genome sequencing and bioinformatics provide a solution to many of the traditional hurdles presented by rare diseases. Whole exome sequencing (WES) approaches, where only the coding sequence of genes is targeted, have proven successful in diagnosing a proportion of children and adults with rare diseases in both the research and diagnostic arenas (5) (6) (7) (8) (9) . Whole genome sequencing (WGS), which unlike WES is not biased to particular genomic regions, is now frequently being performed in the research setting and is beginning to be used for diagnostic purposes. A comparison between the two methods has shown that WGS is the preferred option for testing Mendelian disorders (10) . In the UK WGS is being extended into the healthcare environment through the 100,000 Genomes Project (11, 12), however, feedback of results is currently expected to take many months. Early studies in the USA (13, 14) and Netherlands (15) have shown a benefit for rapid sequencing in acutely ill children but these studies have used modified laboratory equipment and working procedures incompatible with standard diagnostic laboratory practices or have analysed a pre-determined gene list, respectively.
For this study, rapidity of diagnosis is not the only or even most important issue to address as sustainability of a rapid genome sequencing service in the context of a NHS diagnostic laboratory is of paramount importance. The aim of this study was therefore to expand on previous rapid sequencing studies by developing the first end-to-end workflow using rapid WGS to diagnose critically ill children in an NHS setting. Specifically, this begins with the identification of an eligible patient on the paediatric intensive care unit (PICU) and ends with the delivery of a diagnostic report. To do this we set up a multidisciplinary team to ensure our workflow seamlessly transitioned between the various specialities. We adopted a fully prospective two-stage approach whereby the first 10 trios were used to iteratively develop a workflow which was then applied to the next 14 trios.
An essential goal of this study was to develop a workflow integrated within an existing service laboratory that could be adopted by other diagnostic centres. To achieve this we only used off-the-shelf products and equipment and designed our protocol to fit with standard working practices. We make this information freely available for others to use.
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Methods
The study was undertaken in a UK National Health Service (NHS) tertiary children's hospital with a 23-bedded multi-disciplinary PICU and a 20 bed paediatric cardiac intensive care unit.
The study has UK Research Ethics Committee approval REC reference 08/H0713/82. Signed informed parental consent for participation in this study was obtained in all cases.
RaPid Sequencing (RaPS) Team:
We established a multidisciplinary RaPS team consisting of clinical geneticists, research and clinical scientists. The RaPS team was supported by paediatric intensive care unit (PICU) clinicians and other paediatric specialist teams who identified critically ill individuals for inclusion. Our workflow comprises detailed inclusion and exclusion criteria, clinical data capture and conversion to Human Phenotype Ontology (HPO) terms, rapid DNA extraction and WGS, a rapid bioinformatics analysis pipeline, tiered reporting of potentially causative variants, multidisciplinary team discussion, and validation of results in an accredited NHS diagnostic laboratory ( Figure 1 ).
Inclusion criteria:
Suitable participants were clinically ascertained by a specialist physician or PICU consultant between August 2015 until October 2017. The first 10 trios were run as proof-of-principle to establish workflow systems. This allowed us to iteratively review our inclusion criteria and led to the development of the following list that we applied to the remaining 14 trios: Using these criteria we aimed to identify individuals with a high likelihood of having a monogenic disorder and focused on those individuals in whom achieving a genetic diagnosis would be likely to inform clinical management in the acute setting. We also excluded individuals who were felt to be at high risk of imminent demise. For this group of children standard diagnostic testing or access to WGS through the 100,000 Genomes Project (100KGP) (7) was suggested where appropriate in order to offer an explanation and inform future genetic counselling for their parents and family members.
Recruitment and Consent:
To expedite the identification and pathogenic assessment of causative genes we recruited biological trios consisting of proband and both parents (14) . A template for recording clinical and family history at time of consent was developed in order to standardise data capture and improve workflow. Phenotypic information provided by a clinical geneticist, or specialist paediatrician was captured as HPO terms to facilitate bespoke gene panel design for each patient ( Supplementary Table 1 ).
Participants were given the choice of opting in or out of return of secondary findings as guided by recommendations from the American College of Medical Genetics and Genomics (ACMG) (16) .
Genomic Assays:
Detailed methods are found in Supplementary Material 2. Briefly, DNA was extracted using (19) to detect potential structural variants on the second allele.
Data were analysed in a three-stage process (Phase I-III) to prioritise likely causative genes and facilitate prompt return of results ( Figure 1 ). All putative pathogenic calls were manually assessed using IGV to ensure they were true variants and not technical artefacts.
Phase I analysis:
In Phase I we restricted the genes analysed to those with a high probability of being identify potential collaborators with variants in the same gene.
Multi-disciplinary Review:
Variants identified from Phase I and II analysis were triaged by the core RaPS team including a Clinical geneticist and research scientists. Any variants deemed to be potentially relevant to the individual's phenotype were scored according to ACMG variant interpretation guidelines (24) . These were then reviewed in a genomic multidisciplinary team (MDT) meeting comprising at least two clinical geneticists, the referring team when available and clinical and research scientists in order to determine a consensus on pathogenicity and the need for further investigations.
Feedback of Results:
Variants assessed as pathogenic or likely pathogenic and contributing to the individual's phenotype following MDT discussion were fed back to referring clinicians. At this point a provisional research results report was generated. Diagnostic results were validated in an 10 accredited laboratory using Sanger sequencing. If no likely pathogenic variants were identified after Phase II analysis, a 'no primary findings' research results report was issued to the referring clinical team detailing the analysis performed and plan for continued research analysis.
Role of funding source:
The funding source had no role in the design of the study, the collection, analysis, or interpretation of the data, or the writing of the report. Authors; LB, EC, WJ, JH, SR, MB and HW had access to the raw data.
Results
RaPS workflow: from patient to variant:
Individuals recruited were on average known to eight specialist medical teams in the hospital (Figure 2 and Supplementary Figure 1 ). Mean age of affected individuals at point of sequencing was 15·86 months (range 7 days-13y 2 months) with a median age of 2.5 months ( Supplementary Figure 2) .
Whole genome sequencing of the 24 trios generated an average of 5·8 million genomic variants per trio (Supplementary Table 2 ), including those seen in only one parent. The time taken for read mapping and variant calling of the sequence data using the GENALICE appliance ranged from 10 to 40 minutes with an average time of 19 minutes per sample. The number of variants per workflow stage and phase is indicated in Supplementary Figure 3 .
Our coverage metrics showed that on average 88% of the proband's genome had at least 10X coverage and an average of 67% of the parent's genome had at least 10X coverage (Supplementary Table 3 ). Similar coverage rates were obtained for the coding regions investigated during variant interpretation.
A primary molecular diagnosis (classified as a diagnosis accounting for the majority of an individual's phenotype) was achieved in ten out of 24 trios (42%) ( Table 1) . Of note, all diagnoses were made in Phase I analysis ( Supplementary Table 4 ). Diagnostic variants comprised four de novo mutations, three pairs of compound heterozygous variants and three homozygous variants.
In addition to the diagnostic variants identified in Phase I, a diagnostic 5'UTR expansion in EIF4A3 was identified in an individual (RaPS_04) by a collaborative group (25) and not detected by our WGS analysis. In a further case we confirmed a previously identified IL2RG variant in a proband with immune deficiency. The referring team had requested RaPS analysis with a suspicion that there may be a second cause of the observed clinical features;
however, no additional putatively causal variants were identified (Table 1) .
In Phase II analysis a secondary finding was identified in one individual (RaPS_18). This comprised a homozygous variant in BCHE. Variants in BCHE are associated with postanaesthetic apnoea (Table 1) .
Timelines for diagnosis:
The shortest time taken to complete the full workflow (from consent to return of provisional diagnosis) was five days (RaPS_11). To allow a comparison to previous studies (13-15) we also measured the time to diagnosis for the last 14 trios from the point library preparation began to return of the provisional result. The shortest time for this time period was 4 days with a median time of 7 days (SD+/-9.6 days) ( Figure 3 ). This timeline reflects 'real life' and is based on the standard working hours of a diagnostic laboratory and includes technical delays caused by reagent failure or lack of availability of sequencers. The turnaround time for the first 10 'proof of principle' cases were much more variable whilst systems and workflow was being established. Other factors that resulted in an increased time to diagnosis include delays before the library preparation started and included the non-availability of a parent for consent or blood draw.
Impact of results on clinical management:
In all families where a genetic diagnosis was achieved, diagnosis enabled counselling about prognosis, avoidance of unnecessary investigations and informed recurrence risk. In three individuals (RaPS_02, 11 and 16), a rapid diagnostic result had an immediate impact on the individual's clinical management.
In the first individual, a molecular diagnosis of COL3A1 (RaPS_02) associated with vascular EDS helped explain the presence of a ruptured spleen in this individual; prior to this genetic 13 diagnosis child protection concerns had been raised. Secondly, individual RaPS_11, who presented with renal failure was found to have a de novo WT1 mutation. This genetic diagnosis explained the renal phenotype and also informed the need for bilateral nephrectomy to prevent the development of Wilms tumours that are frequently associated with WTS1 mutations (26) . Finally, the broad approach was especially successful in diagnosing RaPS_16 with Sotos syndrome, an overgrowth disorder (MIM117550). This individual was severely ill with hyperinsulinaemia, and multi-system involvement. The diagnosis of Sotos syndrome was unlikely to have been made for many months in this individual as the clinical features were atypical. A diagnosis of Sotos syndrome assisted in the endocrine management of the hyperinsulinaemia by making further planned investigations unnecessary and advising that this was likely to be self-limiting.
Discussion
We have developed a robust and readily adoptable protocol for achieving rapid end-to-end WGS-based analysis to support the diagnosis of critically ill children. Our workflow comprises detailed inclusion criteria, clinical data capture using HPO terms, rapid DNA extraction and WGS, a rapid bioinformatics analysis pipeline, and tiered variant reporting.
We have successfully applied this workflow in critically ill children on an intensive care unit in a UK NHS setting and obtained a diagnostic rate of 42% (Table 1) . This is a higher diagnostic rate than that obtained in a recently reported study that utilised exome sequencing (9) . Furthermore, our time to diagnosis is greatly reduced using WGS, with the shortest time taken to reach a provisional diagnosis being just four days (Figure 3 ). In three individuals It is important to distinguish the difference between our study and that of other groups who have also performed rapid WGS on critically ill children (13) (14) (15) ). In the studies by the Kingsmore group, the time to diagnosis was far quicker owing in part to the manufacturer reconfiguration of the sequencer used and their protocol requiring staff to be available to perform each stage on a non-stop 24 hour cycle. While in the study by van Diemen and colleagues, the analysis of variant data was greatly simplified by analysing a pre-determined list of 3426 genes in all samples. It is also unclear how best to compare our time scales to previous studies as in the calculation of total time they assume no time interval between the various steps of the protocol. Here, we describe a protocol using off-the-shelf reagents and equipment, which fits into the standard working practices of a diagnostic laboratory. We also combine the benefits of a tiered analysis strategy based on a bespoke WGS panel whilst also affording the option of broader unbiased analysis if a diagnosis is not forthcoming.
At present we calculate the cost of running a rapid WGS trio is approximately £5600 but this is likely to fall and needs to be considered in the context of the cost of an ICU bed, estimated to be £4500/day. This cost also compares favourably with the 26 hour protocol previously reported (13) in which reagents were estimated at $6500 per person ($19500 per trio). A full health economics study would be beneficial to extrapolate the health benefits of a rapid diagnosis (versus one taking several months) in this group of severely ill complex individuals as preliminary data suggests sequencing could save up to $7640 per family (30). In the future, all ill patients with suspected genetic disorders will likely have access to WGS. Until then it is important to carefully select those who will benefit most. Given the costs involved in managing critically ill individuals, a rapid genetic diagnosis in this group may ultimately be the most cost effective option for the NHS and other healthcare providers.
In summary, we have presented a sustainable end-to-end workflow for using WGS to rapidly diagnose critically ill individuals with likely monogenic genetic disorders. Such a workflow utilises off-the-shelf products and could readily be adopted by other diagnostic centres. 
